SG10202100861TA - Substituted carbonucleoside derivatives useful as anticancer agents - Google Patents

Substituted carbonucleoside derivatives useful as anticancer agents

Info

Publication number
SG10202100861TA
SG10202100861TA SG10202100861TA SG10202100861TA SG10202100861TA SG 10202100861T A SG10202100861T A SG 10202100861TA SG 10202100861T A SG10202100861T A SG 10202100861TA SG 10202100861T A SG10202100861T A SG 10202100861TA SG 10202100861T A SG10202100861T A SG 10202100861TA
Authority
SG
Singapore
Prior art keywords
anticancer agents
derivatives useful
substituted
carbonucleoside derivatives
substituted carbonucleoside
Prior art date
Application number
SG10202100861TA
Inventor
Robert Arnold Kumpf
Indrawan James Mcalpine
Michele Ann Mctigue
Ryan Patman
Eugene Yuanjin Rui
John Howard Tatlock
Michelle Bich Tran-Dube
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG10202100861TA publication Critical patent/SG10202100861TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SG10202100861TA 2016-06-06 2017-06-03 Substituted carbonucleoside derivatives useful as anticancer agents SG10202100861TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346226P 2016-06-06 2016-06-06
US201662376856P 2016-08-18 2016-08-18
US201662431714P 2016-12-08 2016-12-08
US201762506076P 2017-05-15 2017-05-15

Publications (1)

Publication Number Publication Date
SG10202100861TA true SG10202100861TA (en) 2021-03-30

Family

ID=59071035

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202100861TA SG10202100861TA (en) 2016-06-06 2017-06-03 Substituted carbonucleoside derivatives useful as anticancer agents
SG11201810485SA SG11201810485SA (en) 2016-06-06 2017-06-03 Substituted carbonucleoside derivatives useful as anticancer agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201810485SA SG11201810485SA (en) 2016-06-06 2017-06-03 Substituted carbonucleoside derivatives useful as anticancer agents

Country Status (42)

Country Link
US (2) US10220037B2 (en)
EP (1) EP3464249B1 (en)
JP (2) JP6553825B2 (en)
KR (2) KR20210018529A (en)
CN (1) CN109890797B (en)
AU (2) AU2017279014B2 (en)
BR (1) BR112018075166A2 (en)
CA (1) CA2969295A1 (en)
CL (1) CL2018003504A1 (en)
CO (1) CO2018013105A2 (en)
CR (1) CR20180578A (en)
CU (1) CU24517B1 (en)
CY (1) CY1124798T1 (en)
DK (1) DK3464249T3 (en)
DO (1) DOP2018000268A (en)
EC (1) ECSP18090743A (en)
ES (1) ES2890435T3 (en)
GE (1) GEP20217211B (en)
HR (1) HRP20211449T1 (en)
HU (1) HUE056634T2 (en)
IL (2) IL263505B (en)
LT (1) LT3464249T (en)
MA (1) MA45153B1 (en)
MD (1) MD3464249T2 (en)
MX (1) MX2018015094A (en)
MY (1) MY196413A (en)
NI (1) NI201800128A (en)
PE (1) PE20190439A1 (en)
PH (1) PH12018502535B1 (en)
PL (1) PL3464249T3 (en)
PT (1) PT3464249T (en)
RS (1) RS62351B1 (en)
RU (1) RU2712944C1 (en)
SG (2) SG10202100861TA (en)
SI (1) SI3464249T1 (en)
SV (1) SV2018005794A (en)
TN (1) TN2018000424A1 (en)
TW (2) TWI637945B (en)
UA (1) UA124386C2 (en)
UY (1) UY37274A (en)
WO (1) WO2017212385A1 (en)
ZA (1) ZA201807723B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542525B (en) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5)
CN111741964A (en) * 2017-12-05 2020-10-02 安杰斯制药公司 Heterocyclic compounds as PRMT5 inhibitors
CN108997309A (en) * 2018-07-17 2018-12-14 中国科学技术大学苏州研究院 A kind of preparation method of pyrazoles -4- aryl derivatives
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3127290A1 (en) * 2019-01-23 2020-07-30 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
JP2022534998A (en) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Heterocyclic compounds as PRMT5 inhibitors
AU2020293021A1 (en) 2019-06-10 2021-12-23 Lupin Limited PRMT5 inhibitors
CA3164804A1 (en) * 2019-12-18 2021-06-24 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
KR20220124225A (en) * 2020-01-07 2022-09-13 화이자 인코포레이티드 PRMT5 inhibitors for use in methods of treatment of psoriasis and other autoimmune conditions
CN111138355A (en) * 2020-01-17 2020-05-12 成都睿智化学研究有限公司 Preparation method of formaldehyde-substituted aza-condensed ring compound
JP2023512000A (en) 2020-01-31 2023-03-23 ソルヴェイ（ソシエテ アノニム） Process for the production of haloalkyl-substituted pyridine compounds
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN113234079B (en) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 Nucleoside analogs as PRMT5 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP0303160A2 (en) 2001-02-22 2003-12-29 Celltech R&D Limited Phenylalanine enamide derivatives and pharmaceutical compositions thereof
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP1987717A1 (en) 2007-04-30 2008-11-05 Bayer CropScience AG Pyridon carboxamides, agents containing these but not impacting useful plants and method for their manufacture and application
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
ES2562010T3 (en) * 2010-12-02 2016-03-02 Medpacto Inc. Purinylpyridinylamino-2,4-difluorophenylsulfonamide derivative, pharmaceutically acceptable salt thereof, method of preparation thereof and pharmaceutical composition with inhibitory activity against Raf kinase, which contains the same as active ingredient
JP6182593B2 (en) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド Substituted heterobicyclic compounds, compositions and medicaments and uses thereof
UA118548C2 (en) 2012-12-21 2019-02-11 Епізайм, Інк. Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
US20160168185A1 (en) 2013-07-22 2016-06-16 Baylor College Of Medicine Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102499727B1 (en) * 2015-02-25 2023-02-15 아웃센스 다이아그나스틱스 엘티디. body exudate analysis
TW202321249A (en) 2015-08-26 2023-06-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
AU2017279014A1 (en) 2018-12-13
JP2019521100A (en) 2019-07-25
EP3464249A1 (en) 2019-04-10
IL263505A (en) 2019-01-31
HUE056634T2 (en) 2022-02-28
UY37274A (en) 2018-01-31
SG11201810485SA (en) 2018-12-28
KR20190015745A (en) 2019-02-14
DK3464249T3 (en) 2021-09-06
MA45153B1 (en) 2021-10-29
CN109890797A (en) 2019-06-14
CN109890797B (en) 2023-02-28
PH12018502535A1 (en) 2019-10-21
TW201802074A (en) 2018-01-16
IL263505B (en) 2021-04-29
JP6553825B2 (en) 2019-07-31
CL2018003504A1 (en) 2019-02-01
HRP20211449T1 (en) 2021-12-24
TN2018000424A1 (en) 2020-06-15
AU2017279014B2 (en) 2019-08-15
AU2019264640A1 (en) 2019-12-05
PT3464249T (en) 2021-09-22
JP2019194231A (en) 2019-11-07
ZA201807723B (en) 2020-01-29
TWI637945B (en) 2018-10-11
GEP20217211B (en) 2021-01-25
EP3464249B1 (en) 2021-08-11
WO2017212385A1 (en) 2017-12-14
US20170348313A1 (en) 2017-12-07
US10709709B2 (en) 2020-07-14
CA2969295A1 (en) 2017-12-06
IL282167A (en) 2021-05-31
MX2018015094A (en) 2019-08-16
US10220037B2 (en) 2019-03-05
UA124386C2 (en) 2021-09-08
KR102215313B1 (en) 2021-02-17
US20190111060A1 (en) 2019-04-18
RU2712944C1 (en) 2020-02-03
CU24517B1 (en) 2021-06-08
NI201800128A (en) 2019-04-08
MA45153A (en) 2021-04-07
CO2018013105A2 (en) 2018-12-28
SI3464249T1 (en) 2021-11-30
TWI667240B (en) 2019-08-01
CR20180578A (en) 2019-03-05
MD3464249T2 (en) 2021-12-31
NZ748652A (en) 2021-06-25
PL3464249T3 (en) 2021-12-20
CY1124798T1 (en) 2022-11-25
SV2018005794A (en) 2019-03-19
DOP2018000268A (en) 2019-01-31
ECSP18090743A (en) 2019-01-31
RS62351B1 (en) 2021-10-29
PH12018502535B1 (en) 2019-10-21
PE20190439A1 (en) 2019-03-27
CU20180144A7 (en) 2019-07-04
BR112018075166A2 (en) 2019-03-26
ES2890435T3 (en) 2022-01-19
MY196413A (en) 2023-03-29
LT3464249T (en) 2021-10-11
TW201840570A (en) 2018-11-16
KR20210018529A (en) 2021-02-17

Similar Documents

Publication Publication Date Title
IL282167A (en) Substituted carbonucleoside derivatives useful as anticancer agents
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
HK1255045A1 (en) Substituted oxopyridine derivatives
HK1244803A1 (en) Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
IL253381B (en) 9h-pyrrolo-dipyridine derivatives
HRP20190107T1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
IL263157A (en) Anticancer compositions
ZA202002898B (en) Anticancer agents
ZA202006147B (en) Anticancer compounds
EP3515904C0 (en) Benzoimidazole derivatives as anticancer agents
EP3207036A4 (en) Novel small molecule anticancer agents
IL251005B (en) Pyrido-oxazinone derivatives
EP3481806C0 (en) 4-anilino-quinoline compounds as anti-cancer agents
IL247868B (en) Phenylpiperidinecarboxamide derivatives as fungicides
HK1253336A1 (en) Indolotryptoline anticancer agents
GB201720279D0 (en) Anticancer compounds
PT3319956T (en) Substituted oxopyridine derivatives